Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.86 |
| ▸ | CA2 | P00918 | 13/20 | 0.86 |
| ▸ | CA9 | Q16790 | 13/20 | 0.86 |
| ▸ | CA12 | O43570 | 12/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20118964 | 0.92 | CA1 (1.00) | CA1CA2CA9CA12LMNA | |
| SCHEMBL18118186 | 0.79 | AKR1C3 (0.65) | CA1CA2CA9CA12KMT2A | |
| SCHEMBL18118185 | 0.77 | AKR1C3 (0.63) | CA1CA2CA9CA12LMNA | |
| SCHEMBL12793541 | 0.76 | CA12 (0.71) | CA1CA2CA9CA12KMT2A | |
| SCHEMBL721079 | 0.76 | KMT2A (0.64) | CA1CA2CA9CA12KMT2A | |
| SCHEMBL1632277 | 0.75 | CA1 (0.63) | CA1CA2CA9CA12SCN2A | |
| SCHEMBL20118874 | 0.74 | CA2 (0.71) | CA1CA2CA9CA12SCN2A | |
| SCHEMBL481254 | 0.73 | CA12 (0.67) | CA1CA2CA9CA12KMT2A | |
| SCHEMBL1957622 | 0.73 | CA2 (0.76) | CA1CA2CA9CA12SCN2A | |
| SCHEMBL31637511 | 0.72 | KMT2A (0.64) | CA1CA2CA9CA12KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| WO-2005037779-A2 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS USED FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | DNPEP, PREP, DPP4 | CA1 905/4885CA2 2113/4885CA9 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.